Tezepelumab gets ODD in the US for Eosinophilic Esophagitis
Tezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read moreTezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read morePfizer has reported that the Japanese Ministry of Health, Labour and Welfare (MHLW) authorized CIBINQO® (abrocitinib), a novel therapy for
Read moreEctica Technologies is delighted to announce it will be presenting as a corporate sponsor at the upcoming CHI Conference on
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreJanssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read moreIrish biotechnology firm Inflazome announced today that it has closed a share purchase agreement with Swiss pharma giant Roche in
Read moreThe widely used arthritis medicine Actemra (tocilizumab) has demonstrated “excellent effects” in the treatment of the COVID-19 disease. Roche’s promising
Read more